Related Experiment Video

Updated: Oct 17, 2025

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

3.5K

Dyslipidemia and aortic valve disease

Pedro Mata1, Rodrigo Alonso1,2, Leopoldo Pérez de Isla1,3

  • 1Fundación Hipercolesterolemia Familiar, Madrid, Spain.

Current Opinion in Lipidology
|October 11, 2021
PubMed

Insights

Degenerative aortic stenosis (AS) is a common heart valve disease. Controlling risk factors like high cholesterol and lipoprotein (a) may delay AS progression and the need for valve replacement.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Preventive Medicine

Background:

  • Degenerative aortic stenosis (AS) is a prevalent heart valve disease in adults.
  • Understanding AS pathophysiology and risk factors, including lipid factors, is advancing.
  • Low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] play significant roles.

Purpose of the Study:

  • To review the interrelationship of dyslipidemia, particularly hypercholesterolemia and Lp(a), in the development and prognosis of valvular AS.
  • To explore the potential of drug therapies targeting risk factors to delay AS progression.
  • To highlight advancements in early detection and future therapeutic strategies.

Main Methods:

  • Review of recent observational studies and Mendelian randomization studies.
  • Analysis of data from studies like SAFEHEART focusing on lipid factors.
  • Synthesis of current understanding of AS pathophysiology and risk factors.

Main Results:

  • Hypercholesterolemia and Lp(a) are significant predictors of AS development and prognosis.
  • The SAFEHEART study provided key insights into the roles of LDL-C and Lp(a).
  • Emerging evidence suggests that managing lipid risk factors may influence AS progression.

Conclusions:

  • Dyslipidemia, especially elevated LDL-C and Lp(a), is central to AS development and prognosis.
  • New imaging tools offer potential for earlier AS detection.
  • Future therapies targeting proprotein convertase subtilisin/kexin type 9 and Lp(a) may delay AS progression and reduce the need for aortic valve replacement.
Abstract

More Related Videos

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro05:47

Isolation of Mouse Interstitial Valve Cells to Study the Calcification of the Aortic Valve In Vitro

Published on: May 10, 2021

4.2K
Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

8.1K

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
183
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
71
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
88
Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
75
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
66
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
83